RxDoctor Payments Data

Andrea Covington, APRN

Family · Mount Vernon, KYNPI 1598231250

Payments from drug & device makers

$2,686in general payments, 2019–2025

Across 125 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$765
  • AstraZeneca$479
  • Sanofi$469
  • Regeneron Healthcare Solutions, Inc.$306
  • Genentech USA, Inc.$163
  • LEO Pharma Inc.$127
  • plus $376 from 10 others

What the payments were for

  • Food & beverage$2,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,686 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$14,865
Medicare patients
156
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$89,690
Breo ElliptaFluticasone/Vilanterol36$18,105
Spiriva RespimatTiotropium Bromide13$11,462
Ipratropium Bromide252$7,396
SymbicortBudesonide/Formoterol Fumarate27$6,059
Epinephrine24$5,622
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,439
Albuterol Sulfate HfaAlbuterol Sulfate108$2,686
Azelastine Hcl90$1,795
Fluticasone Propionate126$1,256
Montelukast Sodium203$1,211
Levocetirizine Dihydrochloride65$915
Levalbuterol Tartrate HfaLevalbuterol Tartrate15$626
Cephalexin32$393
Azithromycin21$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$765$107,794143 claims
AstraZenecaSymbicort$479$6,05927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Mount Vernon

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →